About BRIDGEBIO PHARMA, INC.
BridgeBio is a biopharmaceutical company focused on developing meaningful medicines for patients with genetic conditions through a decentralized, hub-and-spoke model. The company emphasizes first-in-class or best-in-class therapies and partners with academic institutions to advance research.
Development of first-in-class or best-in-class therapies for genetic conditionsDecentralized hub-and-spoke model for agile and scalable drug developmentPartnerships with academic institutions for advancing early-stage researchConducting clinical trials with over 2000+ patients globallyFocus on genetic conditions with 48 unique disease indications targeted over the past 10 years
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to BRIDGEBIO PHARMA, INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.